IL1RL2 and psoriasis: In keeping with the critical role played by IL-36 in driving psoriatic-like skin inflammation and after the success of preclinical studies [60], IL-36R blocking antibodies have been developed for the treatment of psoriasis and are currently being tested in clinical trials [62,63].